{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.1"}]}],"title":"Major cytogenetic response: Complete"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"}]}],"title":"Major cytogenetic response: Partial"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"}]}],"title":"Minimal"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0"}]}],"title":"None"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.1"}]}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"* Complete cytogenetic response (CCyR) - 0% Ph+ metaphases\n* Partial cytogenetic response (PCyR) - \\>0 to 35% Ph+ metaphases\n* Minor cytogenetic response (mCyR) - \\>35 to 65% Ph+ metaphases\n* Minimal - \\>65 to 95% Ph+ metaphases\n* None - \\>95 to 100% Ph+ metaphases\n* Major cytogenetic response (MCyR) - 0 to 35% Ph+ metaphases. A major response combines both complete and partial responses.","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"up to 66 cycles","title":"Best Complete Cytogenetic Response (CCyR) Categories in Ph+ CML-CP Patients Resistant or Intolerant to Imatinib or Dasatinib - Overall","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}